Alpha Lipoic Acid Ammonium Chloride Berberis Vulga

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Complex Formula: Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This submission involves a complex multi-ingredient formula containing over 33 components — including botanical extracts, B-complex vitamins, homeopathic preparations, bacterial cultures, and porcine biological tissues — whose identity as a single drug entity could not be confirmed in any regulatory database. The TxGNN model returned no predicted indications, and no clinical trials or literature were identified, as the system was unable to resolve this multi-component list to a mappable drug entity. This evaluation therefore functions as a data gap report rather than a standard repurposing assessment.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — no predictions generated)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

The input submitted to the pipeline was a semicolon-delimited list of 33+ distinct ingredients rather than a single drug entity. TxGNN operates on individual drug nodes in the knowledge graph, each mapped via a DrugBank ID. Because:

No DrugBank ID was found for the composite formula as a whole — drugbank_id is null.
No regulatory license exists in either the US FDA database to anchor a canonical drug identity.
The ingredient list spans heterogeneous pharmacological classes: antioxidants (Alpha Lipoic Acid), B-complex vitamins (Riboflavin, Niacinamide, Pyridoxine, Pantothenic Acid, Thiamine), botanical/herbal extracts (Berberis Vulgaris, Black Cohosh, Cinchona, Horse Chestnut, Ranunculus Bulbosus), minerals and homeopathic agents (Silver, Sulfur, Mercuric Oxide, Picric Acid, Silicon Dioxide), live bacterial preparations (Enterobacter cloacae, Proteus vulgaris, Proteus morganii, Salmonella Enterica), and porcine biological tissues (adrenal gland, bone marrow, cartilage, intervertebral disc, umbilical cord).

This combination is characteristic of complex biological/homeopathic preparations, which fall outside the scope of conventional drug repurposing pipelines. Without a resolvable single-entity drug node, TxGNN cannot generate scored predictions.

Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient combination.

Literature Evidence

Currently no related literature available for this multi-ingredient combination as a unified entity.

US Market Information

This product has no US FDA authorizations on record. No NDA, ANDA, or BLA was identified.

Safety Considerations

Please refer to the package insert for safety information.

Note on specific ingredients of concern: Several components in this formula carry well-known safety signals when evaluated individually:

Mercuric Oxide — mercury-containing compound; subject to strict regulatory limits due to systemic toxicity risk

Picric Acid — explosive compound with skin and systemic toxicity concerns

Live bacterial preparations (Salmonella, Proteus, Enterobacter) — pathogenic organisms; use in biological preparations requires regulatory clearance for safety

Black Cohosh — associated with hepatotoxicity signals in pharmacovigilance reports

A formal safety dossier for this product would require individual ingredient risk assessment under applicable regulatory frameworks (e.g., FDA’s guidance on complex drug combinations or homeopathic products).

Conclusion and Next Steps

Decision: Hold

Rationale: The pipeline could not resolve this 33-ingredient composite to any drug node in the TxGNN knowledge graph, and no regulatory approval exists as a reference anchor. Without a mappable drug identity, repurposing prediction is technically infeasible, and safety evaluation cannot proceed through standard pathways.

To proceed, the following is needed:

Clarify product identity: Determine whether this is a licensed homeopathic product, a compounded preparation, or an investigational combination therapy — and obtain the applicable regulatory classification
Identify the primary active ingredient: If one or two components drive therapeutic activity, submit each individually to TxGNN for targeted repurposing analysis
Resolve the DrugBank mapping: For ingredients with known DrugBank IDs (e.g., Alpha Lipoic Acid → DB00166, Berberine → DB04115, Niacinamide → DB00627), individual evaluations can be initiated immediately
Obtain the product package insert or monograph: Required to fill DG001 (safety warnings/contraindications) before any clinical relevance assessment
Regulatory status clarification: Confirm whether this product is intended for US submission, and if so, whether under OTC monograph, NDA, or homeopathic drug product pathway (21 CFR Part 207)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.